Ecobiological composition comprising a combination of active principles capable of preventing and treating skin hyperpigmentation

Abstract

Disclosed is a composition that is advantageously cosmetic, and preferably ecobiological, comprising: - glabridin, or an extract containing same; and - a compound of general formula (I); and the uses thereof, in particular cosmetic and non-therapeutic uses, for preventing and / or treating skin hyperpigmentation, and / or a hyperpigmentary disorder, advantageously actinic lentigo, melasma and / or post-inflammatory hyperpigmentation (PIH).

Description

[0001] DESCRIPTION

[0002] TITLE OF THE INVENTION: Ecobiological composition comprising a combination of active ingredients capable of preventing and treating skin hyperpigmentation.

[0003] FIELD OF THE INVENTION

[0004] The present invention relates to the field of skin care, in particular cosmetic compositions, advantageously ecobiological, and their uses for effectively and sustainably combating hyperpigmentary disorders, in particular skin pigmentation spots.

[0005] STATE OF THE PRIOR ART

[0006] Skin color is primarily due to the presence of a pigment in the epidermis, namely melanin. Melanin is synthesized by specific dendritic cells located in the basal layer of the epidermis, the melanocytes. Melanogenesis is the process by which melanin is produced and takes place in melanosomes. When these melanosomes are loaded with melanin, they are transferred to neighboring epidermal cells, the keratinocytes, via extensions of the melanocyte cell bodies, namely dendrites.

[0007] There are two distinct types of melanin: black to brown eumelanin and yellow to reddish-brown pheomelanin. The ratio of eumelanin to pheomelanin determines the color of skin, hair, feathers, and scales. Skin color, also known as pigmentation, is genetically determined and can therefore vary between individuals depending on the chemical nature of the melanin produced and therefore the ratio of eumelanin to pheomelanin. In addition, skin pigmentation is naturally stimulated by sun exposure, a natural protective phenomenon commonly known as tanning.

[0008] Independently of tanning and constitutive melanogenesis at the origin of skin pigmentation, hyperpigmented areas, or spots, can also appear on the skin and under certain conditions. Among the benign hyperpigmentary disorders, characterized by an abnormal accumulation of melanin with or without exposure to the sun, we can cite actinic lentigo (also called senile lentigo), melasma, or even post-inflammatory pigmentation (PIP) linked to the activation of inflammatory problems, such as acne.

[0009] Actinic lentigo is by far the most common hyperpigmentary lesion. This type of lesion, whose appearance is correlated with age, appears on areas of the skin that have been sensitized by photoexposure such as the face, the back of the hands, the upper limbs and especially the dorsal surface of the forearms, the back, and especially the upper back. The increased level of melanogenesis is due to the internal environment of the melanocyte but also to the paracrine environment linked to the secretion of factors by surrounding cells, such as keratinocytes.

[0010] Post-inflammatory hyperpigmentation (PIH) is a skin pigmentation disorder that can occur after inflammation or injury. It can occur from a variety of causes, including sunburn, burns, skin infections, allergic reactions, skin damage (surgery, injury), trauma, and insect bites. Inflammation and certain inflammatory mediators cause increased melanin production, leading to an area of ​​hyperpigmented skin. PIH can affect any part of the body but is more common in sun-exposed areas (face, hands, and forearms) since ultraviolet (UV) radiation aggravates the condition.

[0011] Melasma is a skin condition that presents as hyperpigmented spots on sun-exposed areas, primarily the face. The causes of melasma are genetic, environmental, and also hormonal, explaining why it affects many women during pregnancy. Recent studies have also highlighted the role of exposure to blue light in the appearance of spots. The biological processes involved remain poorly understood, but changes in the internal environment of the melanocyte and the secretion of pro-pigmenting factors by other skin cell types (keratinocytes, fibroblasts, or endothelial cells) have been described.

[0012] Melanin accumulation in spots can occur in keratinocytes in the epidermis, but also in dermal cells (Gautam et al., 2019, Markiewicz et al., 2022), particularly within macrophages (Watanabe et al., 2013). Macrophages are unable to degrade melanin, resulting in the persistence of spots embedded in the dermis. Fibroblasts are also capable of phagocytosing / absorbing melanin and contributing to the presence of dermal spots (Ando et al., 2020). In addition, fibroblasts secrete numerous factors that impact melanocytes and promote melanogenesis, thus maintaining spot renewal.

[0013] The importance of these dermal phenomena in pigmentary disorders has led to further investigations into the causes of these increased and deleterious exchanges between the dermis and the epidermis. It is now known that hyperpigmentary disorders, and in particular the formation of spots, are associated with an alteration of the dermoepidermal junction (DEJ), which increases with age, but which can also occur following an injury. In particular, it has been shown that a loss of structural integrity of the DEJ is correlated with hyperpigmentation in solar lentigines (Iriyama et al., 2011) but also in melasma lesions (Torres-Âlvarez et al., 2011) and HPI (Silpa-Archa et al., 2017). The weakening of the DEJ induces the leakage of melanin into the dermis (Iriyma et al., 2011, Esposito et al., 2022, Phansuk et al., 2022).It is also known that the activity of matrix metalloproteinases (MMPs), particularly MMP-2, is increased in PIH (Park et al., 2017). This increased activity contributes to the degradation of matrix elements and thus to the weakening of the DEJ.

[0014] The integrity of the DEJ is ensured by numerous structural and functional proteins. In particular, laminin-332 (or laminin-5 or epiligrin) participates in the cohesion of epithelial cells at their basal surfaces and thus determines the polarity of these cells. In parallel, it ensures strong adhesion of keratinocytes to the basement membrane via a hemidesmosome protein complex (Aumailley and Rousselle, 2017). Given the key structural roles of this protein, particularly with regard to keratinocytes and therefore its importance in the integrity of the DEJ, a deficiency in laminin-332 may be associated with the leakage of melanin into the dermis, which in turn triggers or exacerbates hyperpigmentary disorders, in particular the formation of persistent pigment spots.

[0015] Benign hyperpigmentary skin disorders pose no real threat to the health of those affected, but are universally considered highly unsightly, particularly in cultures where an even complexion is considered a manifestation of inner "purity" and youth. Treatments may include depigmenting creams, chemical peels, or even pulsed light and laser therapy. However, these treatments are not always without risks to human health.An emblematic case is that of hydroquinone, an inhibitor of tyrosinase, the enzyme responsible for the polymerization of melanin, which has been widely used as a depigmenting agent, but whose repeated applications with high doses are now associated with certain cancers, exogenous ochronosis, as well as dermatoses and keratoses (Charoo, 2022), which is why the use of hydroquinone is now strictly regulated.

[0016] In the past, hyperpigmented spots were treated primarily with melanin synthesis inhibitors. More recently, alternative approaches have been developed that aim to interfere with the transfer of melanin between melanocytes and keratinocytes.

[0017] For example, document FR 3 085 375 describes the use of alkyl-resorcinols in cosmetics to depigment the skin, in particular by activating Dickkopf 1 (DKK-1). DKK-1 is a protein that inhibits the proliferation and function of melanocytes by inhibiting melanogenesis, notably via the transcription factor Mitf and the production of melanogenic proteins. DKK-1 also affects the transfer of melanin from melanocytes to keratinocytes by suppressing the expression of PAR-2 ​​(for "Protease-Activated Receptor-2"). However, no effect has been shown on the deeper causes of pigmentary disorders and alkyl-resorcinols suffer from a lack of efficacy at topical doses.

[0018] There is therefore a clear need to develop, according to the principles of ecobiology, compositions, particularly cosmetic and non-pharmaceutical, which can effectively and sustainably (i.e. in the short, medium and long term) prevent and / or combat the formation of pigment spots, by acting on the causes of these disorders, which are without risks to health, while exploiting natural skin mechanisms.

[0019] DESCRIPTION OF THE INVENTION

[0020] After extensive research using the ecobiological approach, it is to the Applicant's credit to have identified, in an unexpected and surprising manner, a composition comprising a combination of safe compounds (or active ingredients), suitable for topical use, particularly cosmetic, and which act in synergy to meet the aforementioned needs.

[0021] In accordance with the ecobiological approach to acting on the biological causes of skin disorders, an objective of the present invention is to maintain and / or increase the synthesis of laminin-332 to prevent and / or combat (i) hyperpigmentary disorders of the skin, in particular the formation of skin pigment spots, possibly associated with aging, and / or (ii) any other condition associated with a defect in the production of Laminin-332; in particular a hyperpigmentary disorder such as actinic lentigo, melasma and / or post-inflammatory hyperpigmentation.

[0022] Thus, a first object of the present invention relates to a topical composition, preferably ecobiological, comprising:

[0023] - glabridin, or an extract containing it; and

[0024] - a compound of general formula (I), or one of its salts, in which

[0025] - RI, R2, R4 and R5 are chosen independently of each other as being H, OH, a Ci- group

[0026] Cio-alkyl, a C2-Cio-alkenyl group, a C2-Cio-alkynyl group, a C1-Cio-alkoxy group, a -O-(C=O)-(Ci-Cio-alkyl) group or a -NH-(C=O)-(Ci-Cio-alkyl) group;

[0027] - R3 is selected from H, OH, a C1-C10-alkyl group, a C2-C10-alkenyl group, a C2-C10-alkynyl group, a C1-C10-alkoxy group, a -O-(C=O)-(C1-C10-alkyl) group or a -NH-(C=O)-(C1-C10-alkyl) group;

[0028] - R6 is chosen as being -OH or a C1-C4-hydroxyalkyl group; and

[0029] - L is chosen as a bond, -(CH2)-, -(CH2-CH2)- or -(CH=CH)-.

[0030] According to a particular embodiment, glabridin, or the extract containing it; and the compound of general formula (I), or one of its salts, are active ingredients of the composition of the invention.

[0031] According to a particular embodiment, it is a cosmetic composition, advantageously ecobiological, presented in a form suitable for topical application.

[0032] The glabridin contained in the composition according to the invention corresponds to the molecule of formula (II) following:

[0033] (II).

[0034] It is an isoflavone, a type of isoflavonoid, found in particular in licorice root extract, particularly from the species Glycyrrhiza glabra and which, advantageously, corresponds to the CAS number 59870-68-7.

[0035] The present invention provides various advantages, including:

[0036] (i) it allows the simple and routinely integrable use of an effective composition whose compounds act in synergy, to prevent and / or treat a hyperpigmentation disorder and / or reduce cutaneous hyperpigmentation, advantageously the formation of cutaneous pigment spots;

[0037] (ii) it respects the communities of living cells that make up the skin, which constantly interact with each other and with their environment to maintain the balance of this skin ecosystem; and

[0038] (iii) it is inexpensive. In particular, the combination of compounds according to the present invention has the advantage of inducing the synthesis of laminin-332, and this in a synergistic manner. This increased synthesis of laminin-332 strengthens the structure of the DEJ and, as a result, naturally reduces, without invasive intervention and without interfering with melanogenesis, the leakage of melanin into the dermis, which is the cause of the formation of pigment spots.

[0039] In the context of the invention, the articles "a" and "an" are used to refer to one or more (e.g., at least one) units of the grammatical object of the article. For example, "an element" designates at least one element, i.e., one or more elements.

[0040] As used herein, the terms "about" and "approximately" are used interchangeably and in reference to a measurable value such as a quantity, a time, and the like. These terms are to be understood as encompassing measurement uncertainties of ± 20% or ± 10%, preferably ± 5%, even more preferably ± 1%, and particularly preferably ± 0.1% of the specified value.

[0041] For the purposes of the invention, the various features of the invention may be presented in the form of a range of values. It should be understood that the description of values ​​in the form of a range is for the sole purpose of making reading easier and should not be interpreted as a rigid limitation of the scope of the invention. Accordingly, the description of a range of values ​​should be considered as specifically disclosing all possible intermediate ranges as well as each of the values ​​within that range. For example, the description of an interval from 1 to 6 should be considered as specifically describing each of the ranges it comprises, such as the ranges from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as each of the values ​​within that range, for example, 1; 2; 2.7; 3; 4; 5; 5, 3 and 6. This definition holds regardless of the range of the interval.

[0042] In the context of the invention, the expressions "ecobiological composition", "ecobiological active ingredient" or "ecobiological excipient" mean a composition, an active ingredient or an excipient that is respectful of the person, their interactions with the world, and the planet. In other words, this designates a composition, an active ingredient or an excipient that is respectful of the homeostasis of an individual, their interactions with the world, and the environment. In particular, it designates a composition, an active ingredient or an excipient that is respectful of the communities of living cells that make up the skin (i.e., skin microbiota, keratinocytes, fibroblasts, etc.) that constantly interact with each other and with their environment to maintain the homeostasis / balance of this skin ecosystem.In the context of the invention, the expression "ecobiological approach" refers to the particular approach initiated by the inventor and developed by the Applicant which combines biology and skin ecosystem to help the skin live according to its natural biology, over the long term.

[0043] In the context of the present invention, the expression “Cx-Cy-alkyl” denotes a saturated, linear or branched hydrocarbon chain comprising from x to y carbon atoms.

[0044] In the context of the present invention, the expression “Cx-Cy-alkenyl” denotes an unsaturated, linear or branched hydrocarbon chain, containing at least one double bond, and comprising from x to y carbon atoms.

[0045] In the context of the present invention, the expression “Cx-Cy-alkynyl” denotes an unsaturated, linear or branched hydrocarbon chain, containing at least one triple bond, and comprising from x to y carbon atoms.

[0046] In the context of the present invention, the expression “Cx-Cy-alkoxy” denotes a group -O-(Cx-Cy-alkyl).

[0047] In the context of the present invention, the terms “alkyl”, “alkenyl”, “alkynyl”, “alkoxy” as defined above retain the same definition when they include the name of a group such as, for example, hydroxyalkyl.

[0048] In the context of the invention, the expressions "active compound", "active ingredient" and "active principle" are used interchangeably and designate a substance or a compound which has biological and / or therapeutic properties which underlie a physiological effect. The active compound, active ingredient or active principle is to be distinguished from at least one excipient, preferably present in the composition according to the invention.

[0049] In the context of the invention, the term "excipient" refers to a substance or compound that does not possess any biological and / or therapeutic properties. The excipient guarantees in particular the creation of a particular texture, fragrance and / or color for a cosmetic and / or therapeutic formulation, but also its preservation, storage stability, safety and shelf life, in compliance with regulations. The excipient is to be distinguished from the at least one active compound, the active ingredient or the active principle present in the composition according to the invention.

[0050] In the context of the invention, the expressions "composition for cutaneous application", "for topical use" and "topical" are used interchangeably and designate a composition compatible with application to the skin, mucous membranes, nails, hair and / or scalp, preferably human skin. In the context of the invention, the terms "content", "amount" and "level" are used interchangeably.

[0051] For the purposes of the invention, the terms "laminin-332 protein" and "laminin-332" are used interchangeably.

[0052] In the context of the invention, the expression "cosmetic use for reducing skin hyperpigmentation" means any cosmetic and non-therapeutic use of a product with a view to obtaining a lightening of the shade (natural or not) of the skin.

[0053] In the context of the present invention, unless otherwise stated, the proportions expressed in % correspond to mass percentages relative to the total weight of the entity (eg, cosmetic composition) considered.

[0054] Within the scope of the present invention, all the embodiments described above and below can be combined.

[0055] According to a particular embodiment, the glabridin, advantageously corresponding to the CAS number: 59870-68-7, used in the composition according to the invention is in purified form, preferably with a purity of at least 60%, preferably at least 70%, advantageously at least 80%, even more advantageously at least 90%, or even at least 95% or even 98%.

[0056] The glabridin contained in the composition according to the invention may be of plant or chemical origin, or obtained by biotechnology.

[0057] In practice, the plant-derived glabridin may be derived from a licorice extract, in particular a glycolic extract of licorice roots. Thus, the raw materials corresponding to the INCI Glabridin may be used in the composition according to the invention, such as the cosmetic raw material GLABRILIANCE 95% marketed by the company GIVAUDAN. Other suitable raw materials are the extracts corresponding to the INCI designations Glycyrrhiza glabra root extract, Glycyrrhiza inflata root extract and Glycyrrhiza uralensis root extract, provided that these extracts contain glabridin. For example, the composition according to the invention may contain, as a source of glabridin, the cosmetic raw material POLYOL SOLUBLE LICORICE EXTRACT PT(40) marketed by the company MARUZEN and corresponding to the INCI designation Glycyrrhiza glabra (licorice) root extract.

[0058] According to a particular embodiment, the glabridin, or the extract containing it, used in the composition according to the invention, corresponds to the INCI designation Glycyrrhiza glabra (licorice) root extract or Glabridin. According to a particular embodiment, the compound of general formula (I) used in the composition according to the invention has the following characteristics, taken alone or in combination:

[0059] - RI is chosen as being H or a group -O-(C=O)-(Cl-C10-alkyl), more preferably RI is chosen as being H or -O-(C=O)-CH3;

[0060] - R2 is chosen as being H, a Cl-C10-alkoxy group, an O-(C=O)-(Cl-C10-alkyl) group or a -NH-(C=O)-(Cl-C10-alkyl) group, advantageously R2 is chosen as being H, -O-CH3, -O-(C=O)- CH3 or -NH-(C=O)-CH3, preferably R2 is chosen as being H, -O-CH3 or -O-(C=O)-CH3;

[0061] - R3 is chosen as H, a Cl-C10-alkoxy group, an -O-(C=O)-(Cl-C10-alkyl) group or an -NH-(C=O)-(Cl-C10-alkyl) group, advantageously, R3 is chosen as H, -O-CH3, -O-(C=O)- CH3 or -NH-(C=O)-CH3, preferably R3 is chosen as H, -O-CH3 or -O-(C=O)-CH3;

[0062] - R4 is chosen as being H, a Cl-C10-alkoxy group or a -O-(C=O)-(Cl-C10-alkyl) group, advantageously R4 is chosen as being H, -O-CH3 or -O-(C=O)-CH3;

[0063] - R5 is chosen as being H, a Cl-C10-alkoxy group or a -O-(C=O)-(Cl-C10-alkyl) group, preferably, R5 is chosen as being H, -O-CH3 or -O-(C=O)-CH3;

[0064] - R6 is chosen as being a Cl-C4-hydroxyalkyl group, advantageously R6 is chosen as being -CH2OH;

[0065] - L is chosen to be a -(CH2)-, -(CH2-CH2)- and / or -(CH=CH) bond, advantageously -(CH2)-.

[0066] According to a particular embodiment, the compound of general formula (I) used in the composition according to the invention corresponds to the following structure of general formula (Ia): in which RI, R2, R3, R4 and R5 are as defined above.

[0067] According to a particular embodiment, the compound of general formula (I) used in the composition according to the invention corresponds to [N-(l-hydroxydodecan-2-yl)-3,5-dimethoxybenzamide], to [(N-[l-(Hydroxymethyl)undecyl]-3,4-dimethoxybenzeneacetamide)] or to [(N-[l-(Hydroxymethyl)undecyl]benzeneacetamide)] corresponds to the following structure of general formula (lb):

[0068] According to an advantageous embodiment, the compound of general formula (I) used in the composition according to the invention corresponds to [N-(l-hydroxydodecan-2-yl)-3,5-dimethoxybenzamide] corresponds to the following structure of general formula (lb):

[0069] According to a particular embodiment, the compound of general formula (I), or one of its salts, corresponds to I NCI Sphingomonas ferment extract or Hydroxydodecyl Dimethoxybenzamide.

[0070] According to a particular embodiment, the cosmetic raw material Sphingoskine marketed by the company GREENTECH and corresponding to the INCI designation Sphingomonas ferment extract or Hydroxydodecyl Dimethoxybenzamide and to the CAS number 2412366-97-8, advantageously corresponding to the compound of general formula (lb), can be used in the composition according to the invention.

[0071] According to one embodiment, the compound of general formula (I) used in the composition according to the invention corresponds to one of the compounds described in Table 1 below:

[0072] [Table 1]

[0073] The compounds of formula (I) according to the present invention can be prepared by any method known and conventionally used by those skilled in the art, in particular those described in document FR 3085375. According to a particular embodiment, the compound of general formula (I) is included in the composition according to the invention in the form of one of its salts, preferably cosmetically or pharmaceutically acceptable.

[0074] According to a particular embodiment:

[0075] - the compound of general formula (I), or one of its salts, used in the composition according to the invention corresponds to I NCI Sphingomonas ferment extract or Hydroxydodecyl Dimethoxybenzamide; and / or

[0076] - glabridin, or the extract containing it, used in the composition according to the invention corresponds to the INCI designation Glycyrrhiza glabra (licorice) root extract or glabridin.

[0077] According to a particular embodiment, the composition, preferably ecobiological, according to the invention is characterized by the presence of the compound of general formula (I), advantageously the compound of structure (lb), representing between 0.00001% and 5% by total weight of the composition, advantageously between 0.0001% and 1%; and / or glabridin representing between 0.00001% and 5% by total weight of the composition, advantageously between 0.0001% and 1%.

[0078] According to a particular embodiment, the composition, preferably ecobiological, according to the invention is characterized by a mass ratio between glabridin and the compound of structure (I) or one of its salts, advantageously the compound of structure (lb), of between 5:1 and 1:5, advantageously between 2:1 and 1:2.

[0079] According to a particular embodiment, the composition, preferably ecobiological, according to the invention further comprises at least one depigmenting compound selected from the group consisting of ascorbyl glucoside, acetyl glucosamine, ascorbic acid, magnesium ascorbyl phosphate, ascorbyl sodium phosphate, ascorbyl palmitate, ascorbyl tetraisopalmitate and 3-O-ethyl ascorbate, advantageously ascorbyl glucoside and / or acetyl glucosamine, advantageously said at least one compound represents between 0.00001% and 10% by total weight of the composition, advantageously between 0.0001% and 5%.

[0080] Advantageously, the composition, preferably ecobiological, according to the invention further comprises the following characteristics chosen alone or in combination:

[0081] - the aqueous fraction of the composition according to the invention is chosen to allow at least two bioelectrical parameters to be adjusted, one of which is the redox potential, and the other of which is chosen between the pH and the resistivity, to have a value:

[0082] + between 10 and 28, with regard to the redox potential; + between 5 and 8, with regard to the pH; and

[0083] + a resistivity substantially between 8000 ohms (Q).cm and 80 Q.cm, advantageously between 500 and 100 Q.cm;

[0084] - the aqueous fraction of the composition according to the invention is chosen so that the osmotic pressure of said composition is between 70 and 1500 mosm.L 1 , preferably and preferentially between 100 and 500 mosm.L 1 , even more advantageously between 200 and 400 mosm.L 1 , for example 300 mosm.L 1 or 250 mosm.L 1 ;

[0085] - the composition according to the invention further comprises one or more compounds which can contribute to internal protection by an action which can consist of protection of DNA, a reduction in immunosuppression induced by UV radiation, an anti-radical action or a combined effect of these actions;

[0086] - the composition according to the invention further comprises glycyrrhetinic acid, a derivative or a salt of this acid, used as a soothing agent (anti-inflammatory agent) and representing between 0.01% and 2% by total weight of the composition, advantageously between 0.1% and 1%;

[0087] - the composition according to the invention further comprises an anti-radical agent preserving cellular structures, such as for example vitamin E and / or its liposoluble or hydrosoluble derivatives, in particular tocotrienol and / or tocopherol, representing between 0.001% and 10% by total weight of the composition, advantageously between 0.02% and 2%, preferably 0.04%;

[0088] - the composition according to the invention further comprises a protective agent for the p53 protein, such as for example epigallocatechin gallate (EGCG), representing between 0.001% and 0.1% by total weight of the composition, advantageously between 0.005% and 0.05%;

[0089] - the composition according to the invention further comprises a compound selected from the group consisting of: boldo extracts, hyaluronic acid, hyaluronic acid derivatives, as well as its salts and adenosine, xylitol, mannitol, rhamnose, advantageously the combination of xylitol, mannitol, rhamnose and fructooligosaccharides, preferably representing between 0.1% and 40% by weight of the composition;

[0090] - the adenosine present in the composition according to the invention represents between 0.0001% and 5% by total weight of the composition, advantageously between 0.001% and 1%, preferably between 0.01% and 0.05%;

[0091] - the adenosine present in the composition according to the invention is in a non-phosphated form, advantageously in powder form, and corresponds to the INCI designation ADENOSINE marketed by the company PHARMA WALDHOF;

[0092] - the fructooligosaccharides present in the composition according to the invention, also called oligofructoses or FOS, represent between 0.001% and 10% by total weight of the composition, advantageously between 0.01% and 5%;

[0093] -the composition according to the invention comprises the combination of at least one amino acid or amino acid derivative chosen from the group consisting of ectoin, creatine, ergothioneine and / or carnosine, or their physiologically acceptable salts, and mannitol or a mannitol derivative, advantageously, the composition according to the invention comprises ectoin and mannitol;

[0094] - the carnosine present in the composition according to the invention represents between 0.001% and 5% by total weight of the composition, advantageously between 0.01% and 1%;

[0095] - the ectoin present in the composition according to the invention represents between 0.001% and 10% by weight of the composition, and preferably between 0.01% and 5%;

[0096] - the mannitol or one of its derivatives present in the composition according to the invention represents between 0.01% and 30% by weight of the composition, advantageously between 0.1% and 10%;

[0097] - the hyaluronic acid or one of its salts present in the composition according to the invention is in acid form, salt form, in particular sodium, potassium or magnesium salts, preferably sodium salts;

[0098] - the hyaluronic acid or one of its salts present in the composition according to the invention has a molecular weight (Mw) of between 0.1 kDa and 2 MDa, preferably between 400 and 600 kDa or between 0.1-5 KDa;

[0099] - the hyaluronic acid or one of its salts present in the composition according to the invention represents between 0.0001% and 10% by total weight of the composition, advantageously between 0.001 and 2% by total weight of the composition, even more advantageously between 0.01% and 1% by total weight of the composition;

[0100] - the hyaluronic acid or one of its salts present in the composition according to the invention corresponds to the raw material BIOSODIUM HYALURONATE MMW corresponding to the INCI name SODIUM HYALURONATE marketed by the company DKSH;- the composition according to the invention comprises boldo or a boldo extract. Boldo (Peumus boldus) or boldo extract is a species of tree of the Monimiaceae family and whose leaf extracts induce the synthesis of defensins and cathelicidins, the boldo extract represents between 0.0001% and 10% by total weight of the composition, advantageously between 0.001% and 2%, preferably between 0.01% and 1%;

[0101] - the boldo extract present in the composition according to the invention corresponds to the raw material MP BETAPUR PGF corresponding to the INCI name WATER (AND) BUTYLENE GLYCOL (AND) PEUMUS BOLDUS LEAF EXTRACT (AND) PENTYLENE GLYCOL (AND) XANTHAN GUM marketed by the company BASF;

[0102] - the composition according to the invention further comprises peptide extracts of soy and / or wheat;

[0103] - the peptide extracts of soy and / or wheat present in the composition according to the invention represent between 0.01% and 20% by total weight of the composition, advantageously between 0.1% and 10%, preferably between 0.2% and 0.7%;

[0104] - the soy and wheat peptide extracts present in the composition according to the invention have a weight ratio respectively between 80 / 20 and 20 / 80, advantageously between 70 / 30 and 30 / 70, preferably equal to 60 / 40;

[0105] - the soy and / or wheat peptide extracts present in the composition according to the invention are free from synthetic tripeptides GHK (glycyl-histidyl-lysine; INCI: Tripeptide-1);

[0106] - the soy peptide extract present in the composition according to the invention is the extract identified under the CAS number 68607-88-5 and / or the wheat peptide extract present in the composition according to the invention is the extract identified under the CAS number 70084-87-6, advantageously the wheat and / or soy extracts correspond to the INCI designations HYDROLYZED WHEAT PROTEIN and HYDROLYZED SOY PROTEIN, respectively.

[0107] According to a particular embodiment, the composition, preferably ecobiological, according to the invention is in a galenic form suitable for topical use, in particular cosmetic, acceptable, that is to say compatible with the skin, mucous membranes, nails, hair and / or the scalp.

[0108] In particular, the composition according to the invention is in a galenic form suitable for cutaneous application.

[0109] Thus, the composition according to the invention may be in the form of an aqueous, hydroalcoholic, organic or oily solution; suspension or dispersion in solvents or fatty substances, such as lotion or serum; in the form of a vesicular dispersion; in the form of a water-in-oil (W / O), oil-in-water (O / W) or multiple emulsion such as a water-in-oil-in-water (W / O / W) emulsion. The emulsion may be more or less thick and is in the form of a cream or milk; the composition according to the invention may also be in the form of an ointment, gel, solid stick, pasty or solid anhydrous products, foam, in particular aerosol, two-phase composition or even sprayable composition.

[0110] The galenic form of the composition as well as its method of preparation, and consequently the excipients suitable for the composition according to the invention, can be chosen by the person skilled in the art on the basis of his general knowledge depending on the type of composition sought, preferably in accordance with the ecobiological approach. In particular, the composition can comprise any fatty substance usually used in the cosmetic field. Mention may in particular be made of fatty substances such as oils and waxes of vegetable, mineral, animal and / or synthetic origin. The oils can be volatile or non-volatile. Mention may also be made of synthetic esters and ethers, fatty alcohols and fatty acids.The composition may also comprise an aqueous medium, a hydroalcoholic medium containing an alcohol such as ethanol or isopropanol, or an organic medium comprising usual organic solvents such as Cl-6 alcohols, in particular ethanol and isopropanol, glycols such as propylene glycol, ketones. Of course, the person skilled in the art will take care to choose this or these possible additional adjuvant(s) or excipient(s), and / or their quantity, in such a way that the advantageous properties of the composition according to the invention are not, or not substantially, altered by the envisaged addition. The composition may comprise at least one conventional emulsifier, chosen from amphoteric, anionic, cationic or non-ionic emulsifiers, used alone or as a mixture.It may be particularly advantageous to formulate the composition according to the invention so that it preferably comprises ingredients that are biomimetic of the natural components of the skin. This may be achieved, for example, by formulating specific emulsions comprising particular combinations of excipients.

[0111] Another subject of the invention relates to the cosmetic and non-therapeutic use of the composition, preferably ecobiological, according to the invention to prevent and / or reduce skin hyperpigmentation, advantageously the formation of skin pigment spots.

[0112] According to an alternative embodiment, the invention relates to the composition, advantageously ecobiological, according to the invention for its use in preventing and / or reducing cutaneous hyperpigmentation, advantageously the formation of cutaneous pigment spots; and / or the use of the composition according to the invention, advantageously ecobiological, for preparing a medicament for preventing and / or reducing cutaneous hyperpigmentation, advantageously the formation of cutaneous pigment spots.

[0113] According to another embodiment, the invention relates to a method for preventing and / or reducing cutaneous hyperpigmentation, advantageously the formation of cutaneous pigment spots, comprising the administration, advantageously the topical administration, of the composition according to the invention, advantageously ecobiological.

[0114] Another subject of the invention relates to the non-therapeutic, advantageously cosmetic use of the composition, advantageously ecobiological, according to the invention to prevent and / or treat a dysfunction associated with a defect in the synthesis of laminin-332.

[0115] According to an alternative embodiment, the invention relates to the composition, advantageously ecobiological, according to the invention for its use for preventing and / or treating a dysfunction associated with a defect in the synthesis of laminin-332; and / or the use of the composition according to the invention, advantageously ecobiological, for preparing a medicament for preventing and / or treating a dysfunction associated with a defect in the synthesis of laminin-332.

[0116] According to another embodiment, the invention relates to a method for preventing and / or treating a dysfunction associated with a defect in the synthesis of laminin-332 comprising the administration, advantageously the topical administration, of the composition, advantageously ecobiological, according to the invention.

[0117] Another subject of the invention relates to the non-therapeutic, advantageously cosmetic use of the composition, advantageously ecobiological, according to the invention for preventing and / or treating a hyperpigmentary disorder, advantageously actinic lentigo, melasma and / or post-inflammatory hyperpigmentation (PIH).

[0118] According to an alternative embodiment, the invention relates to the composition, advantageously ecobiological, according to the invention for its use for preventing and / or treating a hyperpigmentary disorder, advantageously actinic lentigo, melasma and / or post-inflammatory hyperpigmentation (PIH); and / or the use of the composition according to the invention, advantageously ecobiological, for preparing a medicament for preventing and / or treating a hyperpigmentary disorder, advantageously actinic lentigo, melasma and / or post-inflammatory hyperpigmentation (PIH).

[0119] According to another embodiment, the invention relates to a method for preventing and / or treating a hyperpigmentary disorder, advantageously actinic lentigo, melasma and / or post-inflammatory hyperpigmentation (PIH), comprising the administration, advantageously the topical administration, of the composition, advantageously ecobiological, according to the invention.

[0120] Another subject of the invention relates to the non-therapeutic, advantageously cosmetic use of the composition, advantageously ecobiological, according to the invention for depigmenting the skin of an individual.

[0121] According to an alternative embodiment, the invention relates to the composition, advantageously ecobiological, according to the invention for its use for depigmenting the skin of an individual; and / or the use of the composition according to the invention, advantageously ecobiological, for preparing a medicament for depigmenting the skin of an individual.

[0122] According to another embodiment, the invention relates to a method for depigmenting the skin of an individual comprising the administration, advantageously the topical administration, of the composition, advantageously ecobiological, according to the invention.

[0123] Another subject of the invention relates to the non-therapeutic, advantageously cosmetic use of the composition, advantageously ecobiological, according to the invention for maintaining and / or increasing the synthesis of laminin-332. According to an alternative embodiment, the invention relates to the composition, advantageously ecobiological, according to the invention as described above for its use for maintaining and / or increasing the synthesis of laminin-332; and / or the use of the composition according to the invention, advantageously ecobiological, for preparing a medicament for maintaining and / or increasing the synthesis of laminin-332. According to another embodiment, the invention relates to a method for maintaining and / or increasing the synthesis of laminin-332 comprising the administration, advantageously the topical administration, of the composition, advantageously ecobiological, according to the invention.

[0124] Another object of the invention relates to the cosmetic and non-therapeutic use of the composition, advantageously ecobiological, according to the invention to regenerate the skin, advantageously to promote the healing of the skin.

[0125] According to an alternative embodiment, the invention relates to the composition, advantageously ecobiological, according to the invention for its use for regenerating the skin, advantageously for promoting the healing of the skin; and / or the use of the composition according to the invention, advantageously ecobiological, for preparing a medicament for regenerating the skin, advantageously for promoting the healing of the skin.

[0126] According to another embodiment, the invention relates to a method for regenerating the skin, advantageously for promoting healing of the skin, comprising the administration, advantageously the topical administration, of the composition, advantageously ecobiological, according to the invention.

[0127] The following examples, without being limiting, form an integral part of the invention and any characteristic which appears to be new compared to the state of the prior art is claimed as such and as a general means.

[0128] FIGURES

[0129] [Fig. 1]: Evaluation of the effect of N-[l-(hydroxymethyl)undecyl]-3,5-dimethoxybenzamide (HDMB; compound of general formula (lb)) and glabridin (GLA), at three different concentrations, alone or in combination, on the synthesis of laminin-332 by normal human keratinocytes (NHK). The results are from an experiment with 3 wells per condition. Statistical tests are performed versus the “DMSO” condition (significance: *: p<0.05; **: p<0.01; ***: p<0.001).

[0130] EXAMPLES OF IMPLEMENTATION The percentages indicated are given by weight of product in relation to the total weight of the composition in the tables below.

[0131] Example 1: Cosmetic composition within the meaning of the invention - O / W emulsion

[0132] A sunscreen composition (SPF 20) in the form of an H / W emulsion according to the invention is described in Table 2.

[0133] [Table 2] Example 2: Cosmetic composition within the meaning of the invention - Cream

[0134] A composition according to the invention is described in Table 3.

[0135] [Table 3] Example 3: Cosmetic composition within the meaning of the invention - Gel

[0136] A composition according to the invention is described in Table 4.

[0137] [Table 4]

[0138] Example 4: In vitro evaluation of the effect of the composition according to the invention on the synthesis of laminin-332

[0139] 1. Objective of the study This study aims to determine the induction capacity of two compounds of the invention, alone or in combination, on the synthesis of laminin-332 by KHN.

[0140] 2. Materials and methods

[0141] 2.1. Biological model

[0142] Normal Human Keratinocytes (KHN; Bioalternatives Reference K341 used in 3 emepassage) were used in this study. The cells were seeded in 96-well plates at a rate of 15,000 cells / well in “Keratinocyte SFM” culture medium supplemented with growth factors and bovine pituitary extract. After 24 hours of incubation at 37 C, 5% CO2, the medium is replaced with an assay medium containing or not (control) the compounds of the invention at different concentrations, alone or in combination; the solvent control (DMSO at 5.15 x 10 -3 %) or the positive control (TGF-P at 10 ng / ml). The cells were then incubated for 72 hours at 37 C, 5% CO2. All experimental conditions were carried out in n=3.

[0143] An assessment of cell viability is carried out on the cell lawn using the MTT test and with the aim of normalizing the laminin-332 results to MTT, i.e. to living cells. The principle of the test is based on the use of a tetrazolium salt, MTT ((3-4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) which is reduced to formazan by a mitochondrial enzyme, succinate dehydrogenase of living cells. The quantity of formazan produced is proportional to the metabolic activity of the cells. This insoluble, violet-colored compound must be solubilized with DMSO to allow its spectrophotometric determination at 540 nm. 2.2. The active ingredients tested

[0144] The tested assets are listed in Table 5 below.

[0145] [Table 5]

[0146] 2.3. Immunofluorescent labeling / After the incubation period, the cells were rinsed with PBS solution, fixed and permeabilized. The cells were then labeled using a specific primary antibody (anti-laminin-332). The primary antibody was revealed using an appropriate fluorescent secondary antibody (GAM-Alexa 488) and the cell nuclei were stained in parallel using Hoechst 33258 (bisbenzimide) solution. 2.4. Microscopic observation and image analysis

[0147] Image acquisition (5 photos / well) was performed with an INCell Analyzer™ 2200 (GE Healthcare, x20 objective). Labeling was quantified by measuring fluorescence intensity and normalizing fluorescence intensity to the total cell number (Digital Data Integration with Developer Toolbox 1.5 software, GE Healthcare).

[0148] 2.5. Data analysis

[0149] Raw data were analyzed using Microsoft Excel software.

[0150] Intergroup comparisons were performed by unpaired Student's t-test. Differences were considered statistically significant at p<0.05. (NS: p>0.05; *: p<0.05; **: p<0.01; ***: p<0.001).

[0151] 3. Results and conclusions

[0152] The results are shown in Figure 1.

[0153] It appears that:

[0154] - the “control” condition (or manipulation control) is the detected uninduced basal level of laminin-332 and arbitrarily represents 100% synthesis of laminin-332 protein;

[0155] -the “DMSO” condition is the solvent control of the active ingredients and it slightly but significantly increases the synthesis of laminin-332 (131.6%); the significance of the experimental results with the active ingredients was calculated with respect to this condition;

[0156] - the “positive control” condition (TGFP 10 ng / ml) induces the synthesis of laminin-332 (524.3%), in accordance with what is described in the prior art (Korang et al., 1995). These data validate the chosen model;

[0157] - GLA tested in isolation at three different doses, induced synthesis of laminin-332 at all concentrations. The induction was significant only at the highest concentration, namely 220.3% for the GLA concentration of 3.33xl0 -5 % ;

[0158] - HDMB tested in isolation at three different doses, induced laminin-332 synthesis at all concentrations. The induction was significant only at the highest concentration, 182.8% for the HDMB concentration of 4.1x10 -5 % ;

[0159] - The 3 concentrations of the GLA + HDMB combination lead to a significant induction of laminin-332 production, i.e. 192.1% laminin-332 synthesis for GLA 3.7xl0 -6 % + HDMB 4.56xl0 6 %; 238.7% laminin-332 synthesis for GLA l,llxl0- 5 % + HDMB l,37xl0 5 % and 310.9% synthesis of laminin-332 for GLA 3.33xl0 -5 % + HDMB 4,lxl0 -5%. The synergy between 2 active substances (in this case: N-[l-(hydroxymethyl)undecyl]-3,5-dimethoxybenzamide or HDMB or compound of formula (lb) and glabridin or GLA) is calculated by comparing the results of tests in which the effectiveness of the 2 substances and that of their mixture are measured. In the 3 conditions tested, the combination of GLA and HDMB resulted in an induction of laminin-332 synthesis that was much higher than the sum of the inductions measured for each of the active ingredients tested alone at the same concentrations. This difference is statistically significant for the combination of GLA doses l,llxl0 -5 % + HDMB l,37xl0 -5 % and GLA 3.33xl0 -5 % + HDMB 4,lxl0 -5 %.

[0160] These data demonstrate the synergistic effect between the ingredients GLA and HDMB in a composition according to the invention. In other words, the combination of GLA and HDMB has a significant synergistic effect of increasing the laminin-332 content and therefore on the synthesis of laminin-332 and, ultimately, on the prevention and / or attenuation of cutaneous hyperpigmentation, in particular the formation of cutaneous pigment spots; the prevention and / or treatment of a dysfunction associated with a defect in laminin-332 synthesis and / or a hyperpigmentary disorder, such as actinic lentigo, melasma, and / or post-inflammatory hyperpigmentation.

[0161] BIBLIOGRAPHY

[0162] Ando H, Yoshimoto S, Yoshida M, Shimoda N, Tadokoro R, Kohda H, Ishikawa M, Nishikata T, Katayama B, Ozawa T, Tsuruta D, Mizutani Kl, Yagi M, Ichihashi M. (2020) Dermal Fibroblasts Internalize Phosphatidylserine-Exposed Secretory Melanosome Clusters and Apoptotic Melanocytes. IntJ Mol Sci. 21(16):5789.

[0163] Aumailley M, Rousselle P. (1999) Laminins of the dermo-epidermal junction. Matrix Biol. 18(l):19-28.

[0164] Charoo NA. (2022) Hyperpigmentation : Looking beyond hydroquinone. J Cosmet Dermatol. 21(10):4133-4145.

[0165] Esposito ACC, Cassiano DP, da Silva CN, Lima PB, Dias JAF, Hassun K, Bagatin E, Miot LDB, Miot HA. (2022) Update on Melasma-Part I: Pathogenesis. Dermatol Ther (Heidelb) 12(9):1967-1988.

[0166] Gautam M, Patil S, Nadkarni N, Sandhu M, Godse K, Setia M. (2019) Histopathological comparison of lesional and perilesional skin in melasma: A cross-sectional analysis. Indian J Dermatol Venereal Leprol. 85:367-373

[0167] Iriyama S, Ono T, Aoki H, Amano S. (2011) Hyperpigmentation in human solar lentigo is promoted by Heparinase-induced loss of heparan sulfate chains at the dermal-epidermal junction. J Dermatol Sci. 64(3):223-228.

[0168] Markiewicz E, Karaman-Jurukovska N, Mammone T, Idowu OC. (2022) Post-Inflammatory Hyperpigmentation in Dark Skin: Molecular Mechanism and Skincare Implications. Clin Cosmet Investig Dermatol. 15:2555-2565.

[0169] Korang K, Christiano AM, Uitto J, Mauviel A. (1995) Differential cytokine modulation of the genes LAMA3, LAMB3, and LAMC2, encoding the constitutive polypeptides, alpha 3, beta 3, and gamma 2, of human laminin 5 in epidermal kératinocytes. FEBS Lett. 368(3):556-558.

[0170] Park JY, Park JH, Kim SJ, Kwon JE, Kang HY, Lee ES, Kim YC. (2017) Two histopathological patterns of postinflammatory hyperpigmentation: epidermal and dermal. J Cutan Pathol. 44(2):118-124.

[0171] Phansuk K, Vachiramon V, Jurairattanaporn N, Chanprapaph K, Rattananukrom T. (2022) Dermal Pathology in Melasma: An Update Review. Clin Cosmet Investig Dermatol. 15:11-19.

[0172] Silpa-Archa N, Kohli I, Chaowattanapanit S, Lim HW, and Hamzavi (2017) Postinflammatory hyperpigmentation: A comprehensive overview: Epidemiology, pathogenesis, clinical presentation, and noninvasive assessment technique J Am Acad Dermatol. 77(4) : 591-605. Torres-Âlvarez B, Mesa-Garza IG, Castanedo-Câzares JP, Fuentes-Ahumada C, Oros-Ovalle C, Navarrete-Solis J, Moncada B. (2011) Histochemical and immunohistochemical study in melasma: evidence of damage in the basal membrane Am J Dermatopathol. 33(3): 291-295.

[0173] Watanabe T, Tahira M, Morino S, Horie T, Adachi K, Tsutsumi R, Yamada N, Yoshida Y, Yamamoto O. (2013) Novel morphological study of solar lentigines by immunohistochemical and electron microscopic evaluation. J Dermatol. 40(7):528-32.

Claims

CLAIMS 1. Topical composition, preferably ecobiological, comprising: - glabridin, or an extract containing it; and - a compound of general formula (I), or one of its salts, in which - RI, R2, R4 and R5 are independently selected from each other as H, OH, a C1-C10-alkyl group, a C2-C10-alkenyl group, a C2-C10-alkynyl group, a C1-C10-alkoxy group, a -O-(C=O)-(C1-C10-alkyl) group or a -NH-(C=O)-(C1-C10-alkyl) group; - R3 is selected from H, OH, a C1-C10-alkyl group, a C2-C10-alkenyl group, a C2-C10-alkynyl group, a C1-C10-alkoxy group, a -O-(C=O)-(C1-C10-alkyl) group or a -NH-(C=O)-(C1-C10-alkyl) group; - R6 is chosen to be -OH or a Ci-C group 4 -hydroxyalkyl; and - L is chosen as a bond, -(CH2)-, -(CH2-CH2)- or -(CH=CH)-.

2. Composition according to claim 1, characterized in that the compound of general formula (I) has the following characteristics: - RI is chosen as being H or a group -O-(C=O)-(Ci-Cio-alkyl), more preferably RI is chosen as being H or -O-(C=O)-CH3; and / or - R2 is chosen as H, a C1-C10-alkoxy group, an O-(C=O)-(C1-C10-alkyl) group or a -NH-(C=O)-(C1-C10-alkyl) group, advantageously R2 is chosen as H, -O-CH3, -O-(C=O)-CH3 OR -NH-(C=O)-CH3, preferably R2 is chosen as H, -O-CH3 OR -O-(C=O)-CH3; and / or - R3 is chosen as H, a C1-C10-alkoxy group, a -O-(C=O)-(C1-C10-alkyl) group or a -NH-(C=O)-(C1-C10-alkyl) group, advantageously, R3 is chosen as H, -O-CHs, -O-(C=O)-CH3 OR -NH-(C=O)-CH3, preferably R3 is chosen as H, -O-CH3 or -O-(C=O)-CH3; and / or - R4 is chosen as being H, a C1-C10-alkoxy group or a -O-(C=O)-(C1-C10-alkyl) group, advantageously R4 is chosen as being H, -O-CH3 or -O-(C=O)-CH3; and / or - R5 is chosen as H, a C1-C10-alkoxy group or a -O-(C=O)-(C1-C10-alkyl) group, preferably, R5 is chosen as H, -O-CH3 OR -O-(C=O)-CH3; and / or - R6 is chosen to be a group Ci-C 4 -hydroxyalkyl, advantageously R6 is chosen as being -CH2OH; and / or - L is chosen to be a -(CH2)- bond.

3. Composition according to claim 1 or 2, characterized in that the compound of general formula (I) corresponds to the structure of general formula (Ia) following: wherein R1, R2, R3, R4 and R5 are as defined by one of claims 1 or 2.

4. Composition according to any one of the preceding claims, characterized in that the compound of general formula (I) corresponds to [N-(l-hydroxydodecan-2-yl)-3,5-dimethoxybenzamide], to [(N-[l-(Hydroxymethyl)undecyl]-3,4-dimethoxybenzeneacetamide)] or to [(N-[l-(Hydroxymethyl)undecyl]benzeneacetamide)] corresponds to the structure of general formula (lb) below:

5. Composition according to claim 4, characterized in that the compound of general formula (I) corresponds to [N-(l-hydroxydodecan-2-yl)-3,5-dimethoxybenzamide] corresponds to the structure of general formula (lb).

6. Composition according to any one of the preceding claims, characterized in that: - the compound of general formula (I), or one of its salts, corresponds to INCI Sphingomonas ferment extract or Hydroxydodecyl Dimethoxybenzamide; and / or - glabridin, or the extract containing it, corresponds to the INCI designation Glycyrrhiza glabra (licorice) root extract or glabridin.

7. Composition according to any one of the preceding claims, characterized in that: - the compound of general formula (I), advantageously the compound of structure (lb), represents between 0.00001% and 5% by total weight of the composition, advantageously between 0.0001% and 1%; and / or - glabridin represents between 0.00001% and 5% by total weight of the composition, advantageously between 0.0001% and 1%.

8. Composition according to any one of the preceding claims, characterized in that the mass ratio between glabridin and the compound of structure (I) or one of its salts, advantageously the compound of structure (lb), is between 5:1 and 1:5, advantageously between 2:1 and 1:

2.

9. Composition according to any one of the preceding claims, characterized in that it further comprises at least one depigmenting compound selected from the group consisting of ascorbyl glucoside, acetyl glucosamine, ascorbic acid, magnesium ascorbyl phosphate, ascorbyl sodium phosphate, ascorbyl palmitate, ascorbyl tetraisopalmitate and 3-O-ethyl ascorbate, advantageously ascorbyl glucoside and / or acetyl glucosamine.

10. Composition according to claim 9, characterized in that said at least one depigmenting compound represents between 0.00001% and 10% by total weight of the composition, advantageously between 0.0001% and 5%.

11. Cosmetic and non-therapeutic use of the composition according to any one of claims 1 to 10 for preventing and / or reducing skin hyperpigmentation, advantageously the formation of skin pigment spots.

12. Composition according to any one of claims 1 to 10 for its use in preventing and / or treating a dysfunction associated with a defect in the synthesis of laminin 332.

13. Composition according to any one of claims 1 to 10 for its use in preventing and / or treating a hyperpigmentary disorder, advantageously actinic lentigo, melasma, and / or post-inflammatory hyperpigmentation.

Images